| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01091870 Details | 2015-03-25 Interventional | 2 | 0 | Citric Acid Sildenafil Citr… Sodium Citrate Aneurysm Hemorrhage Intracranial An… Rupture Subarachnoid He… Vasospasm, Intr… Cerebral Vasosp… Rupture of Intr… | Absence of inclusion criteria - | |||
| NCT00779220 Details | 2015-03-25 Interventional | 2 | 152 | Methotrexate Ocrelizumab Arthritis Arthritis, Rheu… Rheumatoid Arth… | - - | |||
| NCT00031135 Details | 2015-03-25 Interventional | 2 | - | Choline Liver Diseases | - - | |||
| NCT00030056 Details | 2015-03-25 Interventional | 2 | - | Molgramostim Sargramostim Pulmonary Alveo… | - - | |||
| NCT01175330 Details | 2015-03-24 Interventional | 3 | [1 Refs] | 39 | Soybean oil, ph… Atrial Fibrilla… Coronary Artery… Heart Diseases Myocardial Isch… Ischemic Heart … | Interim analysis did not reveal of anticipated benefits of intervention - | ||
| NCT01118871 Details | 2015-03-24 Interventional | 4 | 3 | Darunavir Emtricitabine, … Etravirine Ritonavir HIV Infections HIV | - - | |||
| NCT00833768 2007-003885-16 Details | 2015-03-24 Interventional | 3 | 5 | Sevelamer Hyperphosphatem… Kidney Diseases Renal Insuffici… Chronic Kidney … | After an extensive review,the ASPIRE in CKD study was terminated because it was not possible to
complete the study in an appropriate time frame. - | |||
| NCT00796666 Details | 2015-03-24 Interventional | 3 | 131 | Sildenafil Citr… Sitaxsentan Familial Primar… Hypertension Hypertension, P… Pulmonary Arter… Pulmonary Hyper… | Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,
specifically new emerging evidence of hepatic injury. Study terminated early by sponsor, no Week 48 information collected. | |||
| NCT00795639 Details | 2015-03-24 Interventional | 3 | 183 | Sitaxsentan Familial Primar… Hypertension Hypertension, P… Pulmonary Arter… Pulmonary Hyper… | Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,
specifically new emerging evidence of hepatic injury. Study terminated early. | |||
| NCT00738985 Details | 2015-03-24 Interventional | 4 | 0 | Ezetimibe Ezetimibe, Simv… Simvastatin Cardiovascular … Hyperlipidemia,… Hyperlipidemias Hyperlipoprotei… Hyperlipidemia | The study was cancelled due to budget limitations - | |||
| NCT00213577 Details | 2015-03-24 Interventional | 2 | 80 | Botulinum Toxin… Urinary Bladder… Overactive Blad… | the study has concluded normally; - | |||
| NCT00430677 Details | 2015-03-20 Interventional | 2/3 | 423 | Abatacept Mycophenolic Ac… Prednisolone Prednisone Lupus Erythemat… Systemic Lupus … | Terminated due to failure to meet the primary efficacy endpoint in the Short-term Period - | |||
| NCT00031577 Details | 2015-03-19 Interventional | 1 | 11 | Paclitaxel Central Nervous… Glioma Nervous System … Brain and Centr… | Administrative closure 9/22/2006. Decline in enrollment at CHOP. due to competing protocols
with new agents. - | |||
| NCT02028312 Details | 2015-03-18 Interventional | 4 | 0 | Loteprednol Eta… Lubricant Eye D… Dry Eye Syndrom… Eye Diseases Keratoconjuncti… Dry Eye Disease | Per Sponsor - | |||
| NCT00068770 Details | 2015-03-18 Interventional | 2 | 35 | Celecoxib Central Nervous… Nervous System … Brain and Centr… | EORTC trail showed TMZ & RT conferred significant survivial in this population Study ended early when results from another study became available documenting Temozolomide (TMZ) and radiation improved survival, we felt it was unethical to continue this study, our study did not include TMZ. | |||
| NCT01467479 Details | 2015-03-17 Interventional | 3 | 185 | Anti-Retroviral… Interferon alph… Interferon-alph… Interferons Peginterferon a… Ribavirin Hepatitis Hepatitis A Hepatitis C | It was decided by Sponsor on 13 January 2014 to terminate study early at primary efficacy
endpoint as part of a decision to modify drug development plan. It was decided by Sponsor on 13 January 2014 to terminate the study early at the primary efficacy endpoint (SVR12) as part of a decision to modify the drug development plan. Eligible participants completed virologic follow-up after termination. | |||
| NCT01157546 Details | 2015-03-17 Interventional | 1 | 25 | Lidocaine Vomiting Assessment of R… Incidence of Na… Opioid Consumpt… Postoperative P… | Low recruitment rate. In our center, open radical prostatectomies have been almost completely
replaced by robotic prostatectomies. - | |||
| NCT01130701 Details | 2015-03-17 Interventional | 2 | [4 Refs] | 0 | Capecitabine Panitumumab Pancreatic Neop… Pancreatic Canc… | Study never went beyond FDA application for an IND #. FDAA required institutional DSMC which
this institution then lacked. - | ||
| NCT00729365 Details | 2015-03-17 Interventional | 3 | 65 | Angiotensin-Con… Ramipril Diabetes Mellit… Diabetes Mellit… Type 1 Diabetes | Data from other studies showed that study could not be completef successfully The study was terminated prematurely because of new information from the literature from other studies showing that this study could not be successful. Only 59 patients were screened and consented and 46 were found acceptable who were randomized. | |||
| NCT00384605 Details | 2015-03-13 Interventional | 3 | 1000 | N-(3-(4-chlorop… Obesity Overweight | The overall profile does not support development for obesity - |